This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective, double-blind, randomised clinical trial that was carried out at seven general practices in southwest England. Staff independent of the study prepared the randomisation sequence with a block size of 10. Randomisation was stratified by gender and age into four 10-year age bands (20 -29, 30 -39, 40 -49 and 50 -59) . Pharmacists, who had no contact with the participants, prepared drug packs, while research nurses who were blind to the treatment allocation dispensed them. Eradication was assessed by a 13C urea breath test 6 months later. Both the participants and outcome evaluators were blind to the result of the test. The length of follow-up was 2 years. Follow-up was 99% (1,539 patients) for the primary outcome and 92% (1,438 patients) for the secondary outcomes.
Analysis of effectiveness
The analysis of the clinical study was by intention to treat since all patients initially included in the clinical trial were considered in the analysis of effectiveness. A secondary analysis was based on treatment completers only, and only patients with completed follow-up questionnaires were considered. The primary outcome measure was the consultation rate for dyspepsia (epigastric pain) in primary care over 2 years, estimated on the basis of primary care records. Also considered were: all consultations related to dyspepsia (epigastric pain) or to heartburn, reflux, or dysmotility-type symptoms; prescribed dyspepsia treatments; and referrals to secondary care for dyspepsia.
The secondary outcome measures were the frequency and type of symptoms and their impact on quality of life. Symptom frequency was assessed within a 3-month period using 5-point Likert-type scales. Participants rated the frequency of dyspepsia (epigastric pain) symptoms, as well as heartburn and reflux, belching (wind), nausea and bloating, from 1 (none) to 5 (daily). The SF-36 questionnaire was used to assess generic health status (quality of life), where 0 indicated poor health and 100 indicated good health. The baseline comparability of the study groups was not explicitly reported, but it is likely that there were no statistically significant differences between the two groups, given the method of randomisation.
Effectiveness results
The number of people consulting for dyspepsia in primary care was reduced by 35% (55 of 787 versus 78 of 771) over 2 years in the treatment group compared with the placebo group (odds ratio 0.65, 95% confidence interval, CI: 0.46 to 0.94; p=0.021). Therefore, 30 people with H. pylori would have to be treated to prevent one person consulting their doctor for dyspepsia. There was no difference in the numbers consulting for dyspepsia according to gender.
Regular symptoms of dyspepsia (epigastric pain) were reported by 29% fewer participants 2 years after H. pylori eradication treatment than after placebo (odds ratio 0.71, 95% CI: 0.56 to 0.90).
No differences existed between the two groups in any of the quality of life dimensions at 2 years.
Clinical conclusions
The effectiveness analysis showed that H. pylori eradication was effective in reducing symptoms of dyspepsia and
CRD COMMENTARY -Selection of comparators
The rationale for the choice of the comparator (i.e. no treatment) was appropriate. The dosage of the eradication therapy was reported. You should decide whether they are valid comparators in your setting.
Validity of estimate of measure of effectiveness
The effectiveness evidence was derived from a clinical trial, which was appropriate for the study question. The randomised, double-blinded multi-centre design, as well as the use of intention to treat, should ensure the internal validity of the analysis. However, since the clinical trial had been published in a separate study, few details of the design and other features of the study were reported. Nevertheless, power calculations and extensive information on the method of sample selection were reported. The authors stated that the sample of patients enrolled was highly representative of the patient population, as a large sample of individuals was enrolled and few patients were excluded. These issues enhance the robustness of the clinical estimates. Demographic and clinical characteristics of nonparticipants could not be accessed, but the authors stated that patients declining participation were more likely to be male, younger and from lower socioeconomic groups than responders.
Validity of estimate of measure of benefit
No summary benefit measure was used in the analysis because a cost-consequences analysis was conducted. Please refer to the comments in the 'Validity of estimate of measure of effectiveness' field (above).
Validity of estimate of costs
The cost analysis was conducted in accordance with the perspective adopted in the study. Typical NHS sources were used to derive the costs. Extensive details on the unit costs and quantities of resources used were provided. This enhances the possibility of replicating the analysis in other settings. Statistical analyses of the costs were performed, but the cost estimates were specific to the study setting and the impact of using alternative economic estimates was not investigated. The price year was reported, which enables reflation exercises in different time periods.
Other issues
The authors stated that the clinical results were comparable to those observed in other population-based clinical trials. However, few comparisons were made for the economic analysis. The authors noticed that the cost of eradication drugs in the UK is likely to be lower than that used in this analysis. The issue of the transferability of the cost results to other settings was not explicitly addressed and sensitivity analyses were not performed. In effect, the external validity of the cost analysis was low. The study referred to patients with H. pylori and this was reflected in the authors' conclusions.
Implications of the study
The study results appear to support a strategy of community screening and eradication of H. pylori in the general population, although the benefits of the programme have to be balanced against the cost of eradication therapy.
Source of funding
Funded jointly by the South and West NHS Research and Development Directorate and GlaxoSmithKline.
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